PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, USA; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, USA; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA; Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA. Electronic address: ircisner@utmb.edu.\', \'Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, USA; Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, USA; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0028-3908(21)00321-X10.1016/j.neuropharm.2021.108766
?:hasPublicationType
?:journal
  • Neuropharmacology
is ?:pmid of
?:pmid
?:pmid
  • 34454912
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.043
?:rankingScore_hIndex
  • 146
?:title
  • Covid-19 interface with drug misuse and substance use disorders.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all